Israel Englander Compass Therapeutics, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 851,205 shares of CMPX stock, worth $3.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

851,205

Previous 545,088 56.16%

Holding current value

$3.16 Million

Previous $1.04 Million 113.82%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.46 - $2.69 $446,930 - $823,454	306,117 Added 56.16%	851,205 $2.21 Million
Q1 2025 May 15, 2025	BUY	$1.4 - $3.9 $715,723 - $1.99 Million	511,231 Added 1509.97%	545,088 $1.04 Million
Q4 2024 Feb 14, 2025	SELL	$1.35 - $1.98 $182,987 - $268,381	-135,546 Reduced 80.01%	33,857 $49,000
Q3 2024 Nov 14, 2024	SELL	$0.8 - $1.88 $211,481 - $496,981	-264,352 Reduced 60.95%	169,403 $311,000
Q2 2024 Aug 14, 2024	BUY	$1.0 - $1.85 $239,988 - $443,977	239,988 Added 123.85%	433,755 $433,000
Q1 2024 May 15, 2024	SELL	$1.2 - $2.29 $360,390 - $687,744	-300,325 Reduced 60.78%	193,767 $383,000
Q4 2023 Feb 14, 2024	BUY	$1.4 - $1.98 $462,876 - $654,639	330,626 Added 202.26%	494,092 $770,000
Q2 2023 Aug 14, 2023	SELL	$2.64 - $3.48 $2.15 Million - $2.84 Million	-814,937 Reduced 83.29%	163,466 $519,000
Q1 2023 May 15, 2023	BUY	$3.14 - $5.48 $2.81 Million - $4.91 Million	896,456 Added 1093.95%	978,403 $3.2 Million
Q4 2022 Feb 14, 2023	BUY	$2.55 - $5.41 $47,838 - $101,491	18,760 Added 29.69%	81,947 $412,000
Q3 2022 Nov 14, 2022	BUY	$1.9 - $3.37 $67,119 - $119,048	35,326 Added 126.79%	63,187 $144,000

Others Institutions Holding CMPX

# of Institutions

106

Shares Held

101M

Call Options Held

18.2K

Put Options Held

2.51M

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $376M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account